Novartis announced that it has entered into an exclusive global licensing and research collaboration agreement with Regenerex, a biopharmaceutical company based in Louisville, Kentucky, for use of the company's novel Facilitating Cell Therapy, or FCRx, platform. The hematopoietic stem cell-based FCRx platform has been investigated in kidney transplantation to induce stable immunological tolerance, resulting in graft survival without the need for lifelong immunosuppression. This collaboration reaffirms the Novartis commitment to transplant. Beyond transplant, Regenerex's novel platform potentially has curative potential for multiple underserved diseases and will be investigated in the rescue of serious genetic deficiencies such as inherited metabolic storage disorders and hemoglobinopathies.